The Ohio State University and MD Anderson Cancer Center Thyroid Cancer SPORE

俄亥俄州立大学和 MD 安德森癌症中心甲状腺癌孢子

基本信息

批准号：
8548721
负责人：
Matthew D Ringel
金额：
$ 215.05万
依托单位：
OHIO STATE UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2013
资助国家：
美国
起止时间：
2013-09-25 至 2018-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8548721
关键词：
Accounting Address Adverse effects Area Behavior Biological Biological Assay Biological Markers Biological Process Biostatistics Core Budgets Cancer Center Cancer Detection Cancer Patient Cancer Survivor Candidate Disease Gene Case-Control Studies Cells Cessation of life Clinical Management Clinical Research Clinical Trials Collaborations Combined Modality Therapy Complication Continuance of life Critiques Cyclin-Dependent Kinases DNA Dental Detection Development Diagnosis Disease Disease Outcome Distant Metastasis Doctor of Medicine Drug resistance Early Diagnosis Functional disorder Genes Genetic Goals Incidence Individual Indolent Institution Intervention Knowledge Life Long Term Survivorship MEKs Malignant Neoplasms Malignant neoplasm of thyroid Measures Molecular Abnormality Monitor Mutation Neoplasm Circulating Cells Neoplasm Metastasis Ohio Outcome Pain Papillary thyroid carcinoma Partial Remission Pathway interactions Patients Penetrance Phase II Clinical Trials Play Population Predisposition Preventive Property Prospective Studies Proteomics Publishing Quality of life Radioactive Iodine Recommendation Recording of previous events Recurrence Reporting Reproduction spores Research Research Personnel Resistance Risk Role Salivary Glands Stable Disease TNFRSF5 gene Taste Perception Testing Therapeutic Transcript Translational Research Translational Research Working Group Translations United States Universities University of Texas M D Anderson Cancer Center Untranslated RNA Validation Vertebrates Woman Xerostomia base cancer risk cancer stem cell career career development clinical care clinical practice experience genome wide association study human subject protection improved in vivo inhibitor/antagonist medullary thyroid carcinoma meetings men mortality novel novel strategies patient population prevent programs response survivorship tumor tumor progression

项目摘要

DESCRIPTION 3 OVERALL CRITIQUE 3 SPORE PROGRAM ORGANIZATION AND CAPABILITIES 6 SCIENTIFIC COLLABORATIONS 8 PROTECTION OF HUMAN SUBJECTS 10 VERTEBRATE ANIMALS 10 SCIENTIFIC REVIEW OFFICER'S NOTES 10 INDIVIDUAL PROJECTS AND CORES 11 PROJECT 1: Low-Penetrance Genes in the Predispositon to Papillary Thyroid Cancer 11 PROJECT 2: Preserving Salivary Gland Function after Radioiodine Therapy for Thyroid Cancer 15 PROJECT 3: Developing Combination Therapies for Medullary Thyroid Cancer 23 PROJECT 4: Development and Validation of Novel Circulating Medullary Thyroid Cancer Markers 29 CORE A/1: Integrated Clinicopathology and Biorespository Core 34 CORE B/2: Biostatistics Core 38 CORE C/3: Administrative Core 41 DEVELOPMENTAL RESEARCH PROGRAM 43 CAREER DEVELOPMENT PROGRAM 45 COMMITTEE BUDGET RECOMMENDATIONS 48 SPECIAL EMPHASIS PANEL ROSTER DESCRIPTION (provided by applicant): The primary goal of The Ohio State University / M.D. Anderson Thyroid Cancer SPORE is to improve the outcomes and lives of patients with thyroid cancer by identifying genetically "at-risk" individuals allowing for early diagnosis and prediction of tumor behavior, developing new approaches to minimize side effects of treatments, and developing better biomarkers and treatment options for progressive metastatic disease. Several factors support the importance of applying these efforts to thyroid cancer: 1) Thyroid cancer incidence is rising at the fastest rate of all malignancies in the United States and worldwide; it s now the 5th most common malignancy in women and 11th most common in men. 2) Thyroid cancer typically takes an indolent course, thus with the increasing incidence there is an ever enlarging population of individuals (-500,000) surviving long term, many of whom suffer from lifelong effects of initial therapy. 3) For patients with more aggressive forms of thyroid cancer, such as medullary cancer (MTC), there exist no curative therapies or biomarkers that accurately predict outcome from disease or response to particular treatments thereby limiting efforts to individualize therapeutic intensity. In order to achieve our goals, this SPORE application proposes to support a multi-institutional team of experienced investigators from two of the leading institutions in the field with a history of collaborative clinical trials. We have chosen t focus on critical areas of need for rapid translation into clinical practice for thyroid cancer patients with the following four Projects supported by outstanding Cores: 1) Low-penetrance genes in the predisposition to papillary thyroid carcinoma; 2) Biomarker discovery and personalized intervention of radioiodine induced salivary gland damage in thyroid cancer patients; 3) Developing combination therapies for Medullary Thyroid Cancer; and 4) Development and validation of novel circulating medullary thyroid cancer markers. Through these translational Projects, as well as Career Developmental and Developmental Research Programs, we aim to impact on critical areas of need in thyroid cancer clinical management for all forms of thyroid cancer. RELEVANCE: Thyroid cancer incidence is rising. Key issues in clinical care related to predictive testing for more aggressive disease, improving survivorship as many patients live for decades after their diagnosis, improving treatment for patients with aggressive forms of thyroid cancer and improving detection and monitoring of metastases This SPORE addresses these critical areas to improve the outcomes of patients with thyroid cancer.

描述 3 总体评价 3 孢子计划的组织和能力 6 科学合作 8 保护人类受试者 10 脊椎动物 10 科学审查官员的笔记 10 个别项目和核心 11 项目 1：甲状腺乳头状癌易感性的低外显率基因 11 项目 2：放射性碘治疗后保留唾液腺功能甲状腺癌 15 项目 3：开发甲状腺髓样癌的联合疗法 23 项目 4：新型循环甲状腺髓样癌标志物的开发和验证 29 CORE A/1：综合临床病理学和生物仓库核心 34 核心 B/2：生物统计学核心 38 核心 C/3：行政核心 41 发展研究计划 43 职业发展计划 45 委员会预算建议 48 特别强调小组名单描述（由申请人提供）：俄亥俄州立大学 / M.D. Anderson 甲状腺癌 SPORE 的主要目标是通过识别遗传上“高危”个体进行早期诊断和预测来改善甲状腺癌患者的治疗结果和生活肿瘤行为，开发新方法以尽量减少治疗副作用，并为进行性转移性疾病开发更好的生物标志物和治疗选择。有几个因素支持了将这些努力应用于甲状腺癌的重要性：1）在美国和全世界，甲状腺癌的发病率在所有恶性肿瘤中以最快的速度上升；目前，它是女性第 5 大常见恶性肿瘤，男性第 11 大常见恶性肿瘤。 2) 甲状腺癌通常呈惰性病程，因此随着发病率的增加，长期存活的人数不断增加（-500,000），其中许多人遭受初始治疗的终生影响。 3）对于患有更具侵袭性的甲状腺癌（例如髓样癌（MTC））的患者，不存在能够准确预测疾病结果或对特定治疗的反应的治疗方法或生物标志物，从而限制了个体化治疗强度的努力。为了实现我们的目标，该 SPORE 应用程序建议支持由来自该领域两个具有合作临床试验历史的领先机构的经验丰富的研究人员组成的多机构团队。我们选择将重点放在甲状腺癌患者需要快速转化为临床实践的关键领域，并通过以下四个由杰出核心支持的项目：1）易患甲状腺乳头状癌的低外显率基因； 2）放射性碘所致甲状腺癌患者唾液腺损伤的生物标志物发现及个性化干预； 3）开发甲状腺髓样癌的联合疗法； 4) 新型循环甲状腺髓样癌标志物的开发和验证。通过这些转化项目以及职业发展和发展研究计划，我们的目标是影响所有形式甲状腺癌的甲状腺癌临床管理的关键需求领域。相关性：甲状腺癌的发病率正在上升。临床护理中的关键问题涉及更具侵袭性疾病的预测性检测、提高生存率（因为许多患者在诊断后仍可存活数十年）、改善侵袭性甲状腺癌患者的治疗以及改善转移的检测和监测。改善甲状腺癌患者的预后。